Eloxx Pharmaceuticals, Inc. (ELOX): Price and Financial Metrics


Eloxx Pharmaceuticals, Inc. (ELOX): $3.41

-0.16 (-4.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ELOX Stock Price Chart Interactive Chart >

Price chart for ELOX

ELOX Price/Volume Stats

Current price $3.41 52-week high $40.40
Prev. close $3.57 52-week low $3.30
Day low $3.41 Volume 15,690
Day high $3.63 Avg. volume 6,744
50-day MA $5.72 Dividend yield N/A
200-day MA $11.90 Market Cap 7.39M

Eloxx Pharmaceuticals, Inc. (ELOX) Company Bio


Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is based in Waltham, Massachusetts.


ELOX Latest News Stream


Event/Time News Detail
Loading, please wait...

ELOX Latest Social Stream


Loading social stream, please wait...

View Full ELOX Social Stream

Latest ELOX News From Around the Web

Below are the latest news stories about ELOXX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ELOX as an investment opportunity.

Eloxx Pharmaceuticals GAAP EPS of -$0.09

  • Eloxx Pharmaceuticals press release (NASDAQ:ELOX): Q3 GAAP EPS of -$0.09.
  • As of September 30, 2022, we had unrestricted cash and cash equivalents of $24.6 million.
...

Seeking Alpha | November 11, 2022

Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update

Started proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations; topline results expected in the first half of 2023 On track to submit IND application for ZKN-013 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) patients with nonsense mutations cells by the end of 2022 or early 2023 WATERTOWN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted gen

Yahoo | November 10, 2022

Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Trial sites now open in Australia and the United KingdomWATERTOWN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the opening of clinical trial sites for its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. “Rare diseases with nonsense mutations, such as Alport syndrome, are particularly challenging to treat. We are incredi

Yahoo | November 1, 2022

Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal

Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.

Yahoo | September 16, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning!

William White on InvestorPlace | September 15, 2022

Read More 'ELOX' Stories Here

ELOX Price Returns

1-mo -39.11%
3-mo -75.64%
6-mo -71.58%
1-year -88.24%
3-year -98.34%
5-year -98.87%
YTD -87.93%
2021 -82.26%
2020 -45.92%
2019 -38.72%
2018 50.13%
2017 185.31%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6496 seconds.